caa a22 4500 397592027 CHVBK 20180308164941.0 cr unu---uuuuu 161202e199605 xx s 000 0 eng 10.1093/jac/37.suppl_A.145 doi (NATIONALLICENCE)oxford-10.1093/jac/37.suppl_A.145 Rubinstein Ethan Infectious Diseases Unit, Sheba Medical Center, Tel Aviv University Sackler School of Medicine, Tel-Hashomer, Israel Safety profile of sparfloxacin in the treatment of respiratory tract infections [Elektronische Daten] [Ethan Rubinstein] A total of 2081 adult patients with community-acquired lower respiratory tract infections participated in Phase HI clinical trials of sparfloxacin. A total of 1040 patients were randomised to sparfloxacin and 1041 patients received a comparator regimen. Sparfloxacin was administered as a 400 mg loading dose on day 1 followed by 200 mg once daily to patients with community-acquired pneumonia and as a 200 mg loading dose on day 1 followed by 100 mg daily to patients with acute exacerbations of chronic obstructive pulmonary disease. Comparator regimens were amoxycillin/clavulanic acid 500/125 mg tid, amoxycillin 1000 mg tid, a combination of amoxycillin 1000 mg tid plus ofloxacin 200 mg bid or erythromycin 1000 mg bid. The incidence of adverse events, the incidence and severity of antibacterial-related adverse events and the incidence of antibacterial discontinuation due to adverse events were no different among patients treated with sparfloxacin compared with those who received a comparator antibacterial agent. Sparfloxacin appears to be as well tolerated as other oral antibacterial regimens commonly used to treat lower respiratory tract infections. © 1996 The British Society for Antimicrobial Chemotherapy Articles nationallicence Journal of Antimicrobial Chemotherapy Oxford University Press 37(1996-05), 145-160 0305-7453 37<145 1996 37 jac https://doi.org/10.1093/jac/37.suppl_A.145 text/html Onlinezugriff via DOI 1 research-article jats NATIONALLICENCE 856 40 https://doi.org/10.1093/jac/37.suppl_A.145 text/html Onlinezugriff via DOI NATIONALLICENCE 100 1- Rubinstein Ethan Infectious Diseases Unit, Sheba Medical Center, Tel Aviv University Sackler School of Medicine, Tel-Hashomer, Israel NATIONALLICENCE 773 0- Journal of Antimicrobial Chemotherapy Oxford University Press 37(1996-05), 145-160 0305-7453 37<145 1996 37 jac Metadata rights reserved CC BY-NC-4.0 http://creativecommons.org/licenses/by-nc/4.0 nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-oxford